IST:GENIL's EV-to-FCF is ranked worse than 82.65% of 559
companies
in the Drug Manufacturers industry
Industry Median: 19.97
vs IST:GENIL: 77.40
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS's PE Ratio (TTM) for today is calculated as:
Gen Ilac Veglik Urunlerinayi ve Ticaret AS's share price for today is ₺9.32.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺0.152.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS EV-to-FCF Related Terms
Gen Ilac Veglik Urunlerinayi ve Ticaret AS EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS EV-to-FCF Chart
Gen Ilac Veglik Urunlerinayi ve Ticaret AS Annual Data
IST:GENIL vs ZTS, UTHR, VTRS: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS EV-to-FCF vs Drug Manufacturers Industry
Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current Enterprise Value is ₺45,283 Mil.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺585 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) has a EV-to-FCF of 77.40 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Gen Ilac Veglik Urunlerinayi ve Ticaret AS and its competitors. This is 217% above median its historical median of 24.43. According to the industry distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #462 out of 559 companies in the Drug Manufacturers industry, placing it in the top 82.6%.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS's EV-to-FCF too high?
Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current EV-to-FCF of 77.40 is 217% above median its 10-year median of 24.43. The Drug Manufacturers industry median EV-to-FCF is 19.97. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's value of 77.40 is 287.6% above this industry median. Based on the distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #462 out of 559 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Gen Ilac Veglik Urunlerinayi ve Ticaret AS has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gen Ilac Veglik Urunlerinayi ve Ticaret AS's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #462 out of 559 companies for EV-to-FCF. This places Gen Ilac Veglik Urunlerinayi ve Ticaret AS in the lower half of its industry. The industry median EV-to-FCF is 19.97. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's value of 77.40 is 287.6% above this benchmark. While the company's 10-year median is 24.43 vs. the industry median of 19.97, Gen Ilac Veglik Urunlerinayi ve Ticaret AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 19.97, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current EV-to-FCF of 77.40 is 287.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Gen Ilac Veglik Urunlerinayi ve Ticaret AS and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 19.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current EV-to-FCF is 77.40, which is 217% above median its own 10-year median of 24.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) is currently considered Modestly Overvalued. The stock's GF Value™ is ₺8.12, compared to a current price of ₺9.32 — trading 14.8% above its estimated fair value. The current EV-to-FCF is 77.40, which is 217% above median its 10-year median of 24.43 and 287.6% above the Drug Manufacturers industry median of 19.97. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL), the current EV-to-FCF is 77.40 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) Overvalued in 2026?
Based on GuruFocus' analysis, Gen Ilac Veglik Urunlerinayi ve Ticaret AS stock appears to be overvalued.
The current stock price of ₺9.32 is trading 14.8% above its estimated GF Value™ of ₺8.12.
GuruFocus considers Gen Ilac Veglik Urunlerinayi ve Ticaret AS to be Modestly Overvalued.
Key valuation signals for IST:GENIL:
EV-to-FCF: 77.40 (217% above median its 10-year median of 24.43)
GF Value™: ₺8.12 vs. price of ₺9.32 (14.8% above fair value)
Industry Position: 287.6% above the Drug Manufacturers median (#462 of 559)
No single metric tells the full story. See the IST:GENIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS Business Description
Gen Ilac Ve Saglik Urunleri Sanayi ve Ticaret AS is a specialty pharmaceuticals company in Turkey. Its locally manufactured products include Cajex, Contra-K, Epamor, Genkort, Ilopera, among others, while imported products include AvonexPEN, Plegridy, Tecfidera, Regen-D among others.
86GF Score
Get the complete analysis for IST:GENIL
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:GENIL has been successfully added to your 
